ATE500849T1 - Antikoagulans/antithrombose-dual-hemmer mit einem biotin-label - Google Patents

Antikoagulans/antithrombose-dual-hemmer mit einem biotin-label

Info

Publication number
ATE500849T1
ATE500849T1 AT06807029T AT06807029T ATE500849T1 AT E500849 T1 ATE500849 T1 AT E500849T1 AT 06807029 T AT06807029 T AT 06807029T AT 06807029 T AT06807029 T AT 06807029T AT E500849 T1 ATE500849 T1 AT E500849T1
Authority
AT
Austria
Prior art keywords
oligosaccharide
residue
gpiib
spacer
compound
Prior art date
Application number
AT06807029T
Other languages
English (en)
Inventor
Kort Martin De
Boeckel Constant Van
Charles Nicholson
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Application granted granted Critical
Publication of ATE500849T1 publication Critical patent/ATE500849T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT06807029T 2005-10-10 2006-10-06 Antikoagulans/antithrombose-dual-hemmer mit einem biotin-label ATE500849T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05109403 2005-10-10
EP05109962 2005-10-25
PCT/EP2006/067127 WO2007042469A2 (en) 2005-10-10 2006-10-06 Anticoagulant antithrombotic dual inhibitors comprising a biotin label

Publications (1)

Publication Number Publication Date
ATE500849T1 true ATE500849T1 (de) 2011-03-15

Family

ID=37451080

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06807029T ATE500849T1 (de) 2005-10-10 2006-10-06 Antikoagulans/antithrombose-dual-hemmer mit einem biotin-label

Country Status (17)

Country Link
EP (1) EP1991271B1 (de)
JP (1) JP5060486B2 (de)
KR (1) KR20080055960A (de)
AT (1) ATE500849T1 (de)
AU (1) AU2006301331B2 (de)
BR (1) BRPI0617215A2 (de)
CA (1) CA2624588C (de)
DE (1) DE602006020634D1 (de)
EC (1) ECSP088443A (de)
HR (1) HRP20110331T1 (de)
IL (1) IL190523A0 (de)
MY (1) MY145269A (de)
NO (1) NO20081619L (de)
NZ (1) NZ567221A (de)
PL (1) PL1991271T3 (de)
RU (1) RU2434876C2 (de)
WO (1) WO2007042469A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2145624A1 (de) * 2008-07-18 2010-01-20 Sanofi-Aventis Verwendung von Idrabiotaparinux zur Senkung der Blutungsinzidenz bei einer Thrombosebehandlung
TW201006479A (en) * 2008-07-18 2010-02-16 Sanofi Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2233143A1 (de) * 2009-03-24 2010-09-29 Sanofi-Aventis Verwendung von Idrabiotaparinux zur Senkung der Blutungsinzidenz bei einer Thrombosebehandlung
JP6109574B2 (ja) 2009-12-18 2017-04-05 カタラン、フランス、バインハイム、ソシエテ、アノニムＣａｔａｌｅｎｔ Ｆｒａｎｃｅ Ｂｅｉｎｈｅｉｍ Ｓａ 合成オリゴサッカリドを含有する医薬経口剤形
EP2614089A1 (de) * 2010-09-10 2013-07-17 Sanofi-Aventis Biotinylierte polysaccharide mit antithrombotischer wirkung und erhöhter stoffwechselstabilität
JP6051211B2 (ja) * 2011-06-17 2016-12-27 カルボミメティクス 半減期が短く活性が高い合成五糖類

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217869B1 (en) * 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
TWI289566B (en) * 1999-12-07 2007-11-11 N.V.Organon Antithrombotic compound
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
EP1574516A1 (de) * 2004-03-05 2005-09-14 Sanofi-Aventis Antithrombotische Verbindungen

Also Published As

Publication number Publication date
MY145269A (en) 2012-01-13
JP5060486B2 (ja) 2012-10-31
EP1991271B1 (de) 2011-03-09
ECSP088443A (es) 2008-06-30
RU2008118365A (ru) 2009-11-20
BRPI0617215A2 (pt) 2011-07-19
KR20080055960A (ko) 2008-06-19
EP1991271A2 (de) 2008-11-19
AU2006301331B2 (en) 2011-12-22
NZ567221A (en) 2010-06-25
RU2434876C2 (ru) 2011-11-27
CA2624588C (en) 2014-05-20
CA2624588A1 (en) 2007-04-19
WO2007042469A3 (en) 2007-11-29
JP2009511543A (ja) 2009-03-19
HRP20110331T1 (hr) 2011-06-30
NO20081619L (no) 2008-07-03
PL1991271T3 (pl) 2011-08-31
AU2006301331A1 (en) 2007-04-19
DE602006020634D1 (de) 2011-04-21
IL190523A0 (en) 2008-11-03
WO2007042469A2 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
ATE500849T1 (de) Antikoagulans/antithrombose-dual-hemmer mit einem biotin-label
WO2007042470A3 (en) Antithrombotic compound
BRPI0507617A (pt) antagonistas de receptor de quimiocina
BRPI0508461A (pt) diaminopirimidinas como antagonistas de p2x3 e p2x2/3
NO20074149L (no) Nye farmasoytiske sammensetninger for behandling av trombose
UA94593C2 (ru) Антитромбозные двойные ингибиторы с биотиновой меткой
BRPI0507345A (pt) composto antitrombótico
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
BRPI0708490B8 (pt) composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
AR058085A1 (es) Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas.
AR078082A1 (es) Composiciones farmaceuticas que comprenden fucanos modificados, metodos y kits relacionados
BR0309028A (pt) Compostos policìclicos como antagonistas potentes de alfa2-adrenoceptores
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
AU2008228162A1 (en) Low molecular weight heparins including at least one covalent bond with biotin or a biotin derivative, method for making same and use thereof
UA88793C2 (ru) Антитромботические двойные ингибиторы, которые содержат остаток биотина
BR0313384A (pt) Derivados de cromona como inibidores de metaloproteinases de matriz
BRPI0511480A (pt) derivados de azaaçúcar, inibidores de herparanases, seu processo de preparação, as composições que os contêm, sua utilização
WO2007064620A3 (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists
JP2009511543A5 (de)
BRPI0411867A (pt) tiofenilaminoimidazolinas
BR0308807A (pt) Compostos tiazol-2-il-imina como inibidores de pde-7
MX2022014908A (es) Compuestos utiles para inhibir cdk7.
AR099137A2 (es) Formulación para compresión directa y proceso

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties